Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26036976 | 0.77 | MEN1 (0.33) | SIGMAR1PDE2AEPHX2NR1H4CACNA1H | |
| SCHEMBL26014791 | 0.76 | PTGS1 (0.40) | SIGMAR1PDE2A | |
| SCHEMBL26017234 | 0.73 | SLC6A2 (0.30) | — | |
| SCHEMBL19302498 | 0.73 | SIGMAR1 (0.39) | SIGMAR1EPHX2NR1H4CACNA1H | |
| SCHEMBL24196137 | 0.70 | PDK2 (0.39) | SIGMAR1CACNA1H | |
| SCHEMBL19275237 | 0.70 | PDE2A (0.42) | SIGMAR1PDE2AEPHX2NR1H4 | |
| SCHEMBL21035484 | 0.70 | CACNA1H (0.36) | SIGMAR1EPHX2NR1H4WDR5CACNA1H | |
| SCHEMBL21036238 | 0.70 | PDK2 (0.37) | SIGMAR1EPHX2NR1H4WDR5CACNA1H | |
| SCHEMBL24196140 | 0.70 | LOXL2 (0.41) | SIGMAR1CACNA1H | |
| SCHEMBL25735734 | 0.69 | PDK2 (0.40) | SIGMAR1EPHX2NR1H4CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |